The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Changes in ctDNA levels after MIBG therapy in patients with relapsed or refractory neuroblastoma.
 
Kevin M. Campbell
No Relationships to Disclose
 
Kelly S. Klega
No Relationships to Disclose
 
David Stephen Shulman
No Relationships to Disclose
 
Denice D. Tsao-Wei
No Relationships to Disclose
 
Susan G. Groshen
No Relationships to Disclose
 
Fariba Goodarzian
No Relationships to Disclose
 
Rachel Berkovich
No Relationships to Disclose
 
Hiroyuki Shimada
No Relationships to Disclose
 
Araz Marachelian
Research Funding - Pfizer (Inst); United Therapeutics (Inst)
 
Judith Villablanca
No Relationships to Disclose
 
Julie R. Park
No Relationships to Disclose
 
Meaghan Granger
No Relationships to Disclose
 
Katherine K. Matthay
Consulting or Advisory Role - Resonance
 
Brian D. Crompton
Employment - Acceleron Pharma (I); Mersana (I); Shire (I)
Stock and Other Ownership Interests - Acceleron Pharma (I); Mersana (I); Shire (I)
Research Funding - Gradalis
 
Steven G. DuBois
Consulting or Advisory Role - Bayer
Research Funding - Bayer (Inst); BMS (Inst); Curis (Inst); Eisai (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Salarius Pharmaceuticals (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Roche/Genentech; Salarius Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Ymabs Therapeutics Inc